12 Sep 2024 by admin in UncategorizedComments Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
03 Sep 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
20 Aug 2024 by admin in UncategorizedComments Renowned Myeloma Experts Dr. Kenneth C. Anderson and Dr. Shaji Kumar join Scientific Advisory Board of Oricell Therapeutics
19 Aug 2024 by admin in UncategorizedComments Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
08 Aug 2024 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
15 Jul 2024 by admin in UncategorizedComments Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma
15 Jul 2024 by admin in UncategorizedComments Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)
09 Jul 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 Jul 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
25 Jun 2024 by admin in UncategorizedComments Alebund’s Innovative Investigational Drug AP306 Receives NMPA’s Breakthrough Therapy Designation (BTD) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease (CKD)
